EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma

Kazuki Shimizu, Satoshi Tamada iD, Yudai Matsuoka, Ishun Go, Satoshi Okumura, Masao Ogawa, Tetsuji Ohmachi

International Cancer Conference Journal · 2022-07 · 11 (3) · 205-209

DOI: 10.1007/s13691-022-00549-8 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Cancer Conference Journal, online erschienen am 19.04.2022. Verfasst von Kazuki Shimizu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Bell Land General Hospital, 500-3, Higashiyama, Naka-ku, Sakai City, Osaka 599-8247 Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy-based combinations have played a central role in the treatment of metastatic renal cell carcinoma, and long-term survival of patients is expected. In this context, it is clear that a certain number of patients can achieve a complete response. However, the diagnosis of complete response is usually based on imaging, and there are few cases of pathological complete response. In this study, we report a case of a patient with metastatic renal cell carcinoma who was treated with pembrolizumab plus axitinib, followed by resection of the primary tumor and metastatic lesions, and pathologically achieved a complete response.

Schlagwörter

Stichwörter der Autor:innen

Complete responseMetastatic renal cell carcinomaPathologicalPembrolizumab plus axitinib

Autor:innen und Institutionen

  • Department of Urology, Bell Land General Hospital, 500-3, Higashiyama, Naka-ku, Sakai City, Osaka 599-8247 Japan.
  • Department of Surgery, Bell Land General Hospital, Sakai City, Japan.

ORCID-Profile: Satoshi Tamada

Zitieren

APA

Shimizu, K., Tamada, S., Matsuoka, Y., Go, I., Okumura, S., Ogawa, M., & Ohmachi, T. (2022). Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma. International Cancer Conference Journal, 11(3), 205-209. https://doi.org/10.1007/s13691-022-00549-8

Vancouver

Shimizu K, Tamada S, Matsuoka Y, Go I, Okumura S, Ogawa M, et al. Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma. International Cancer Conference Journal. 2022;11(3):205-209. doi:10.1007/s13691-022-00549-8

BibTeX
@article{Shimizu2022,
  author = {Shimizu, Kazuki and Tamada, Satoshi and Matsuoka, Yudai and Go, Ishun and Okumura, Satoshi and Ogawa, Masao and Ohmachi, Tetsuji},
  title = {Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma},
  journal = {International Cancer Conference Journal},
  year = {2022},
  volume = {11},
  number = {3},
  pages = {205--209},
  doi = {10.1007/s13691-022-00549-8}
}
Kostenlos starten →